{"id":685474,"date":"2024-01-23T16:42:01","date_gmt":"2024-01-23T16:42:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=685474"},"modified":"2024-01-23T16:42:01","modified_gmt":"2024-01-23T16:42:01","slug":"familial-chylomicronemia-syndrome-was-around-usd-15-million-in-2022-estimates-delveinsight","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/familial-chylomicronemia-syndrome-was-around-usd-15-million-in-2022-estimates-delveinsight_685474.html","title":{"rendered":"Familial Chylomicronemia Syndrome was around USD 15 million in 2022, estimates DelveInsight"},"content":{"rendered":"<div style=\"float:right;  width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1706003488.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Familial Chylomicronemia Syndrome was around USD 15 million in 2022, estimates DelveInsight\" src=\"https:\/\/www.abnewswire.com\/uploads\/1706003488.jpeg\" alt=\"Familial Chylomicronemia Syndrome was around USD 15 million in 2022, estimates DelveInsight\" width=\"225\" height=\"225\" \/><\/a><\/div>\n<p style=\"text-align: justify;\"><strong><em>&ldquo;The Familial Chylomicronemia Syndrome Market is expected to surge due to the disease&rsquo;s increasing prevalence and awareness during the forecast period (2023-2034). Furthermore, launching various multiple- Familial Chylomicronemia Syndrome pipeline products will significantly revolutionize the Familial Chylomicronemia Syndrome market dynamics<\/em><\/strong>&rdquo;<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\">The Familial Chylomicronemia Syndrome market report provides current treatment practices, Familial Chylomicronemia Syndrome emerging drugs, market share of individual therapies, and current and forecasted 7MM Familial Chylomicronemia Syndrome market size from 2020 to 2034. The report also covers current Familial Chylomicronemia Syndrome treatment market algorithms and unmet medical needs to curate the best opportunities and assess the market&rsquo;s underlying potential.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Takeaways from the Familial Chylomicronemia Syndrome Market Research Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The expected launch of therapies and better diagnosis will lead to market growth during the forecast period (2023-2034).<\/li>\n<li>According to DelveInsight analysis, majority of the cases were accounted by 0-17 years in 2022, in the 7MM.<\/li>\n<li>As per DelveInsight&rsquo;s analysis, Familial Chylomicronemia Syndrome Diagnosed Prevalent Cases based on age were categorized into two age-groups, 0&ndash;17 years and &ge;18 years.<\/li>\n<li>The leading Familial Chylomicronemia Syndrome Companies working in the market include <strong><em>Ionis Pharmaceuticals Inc., Akcea Therapeutics, Novartis Pharmaceuticals, Arrowhead Pharmaceuticals, UniQure Biopharma B.V.,<\/em><\/strong> and others.<\/li>\n<li>Promising Familial Chylomicronemia Syndrome Pipeline Therapies in the various stages of development include <strong><em>ARO-APOC3, sterile normal saline (0.9% NaCl), LCQ908, Olezarsen, Volanesorsen, AKCEA-ANGPTL3-LRx<\/em><\/strong>, and others.<\/li>\n<li>December 2023: Ionis Pharmaceuticals announced a study of Phase 3 clinical trials for Olezarsen. The purpose of this study is to evaluate the effect of olezarsen (formerly known as AKCEA-APOCIII-LRx) on the percent change in fasting triglycerides (TG) from baseline.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about therapies set to grab major Familial Chylomicronemia Syndrome Market Share @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/familial-chylomicronemia-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Familial Chylomicronemia Syndrome Market Size<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Familial Chylomicronemia Syndrome Overview<\/strong><\/p>\n<p style=\"text-align: justify;\">Familial Chylomicronemia Syndrome (FCS) is a rare genetic lipid disorder, which is characterized by the increase in the levels of triglycerides (TGs) due to mutation in the LPL gene. Disease-causing variants in five other genes namely, APOA5, APOC2, GPD1, GPIHPB1, and LMF1 may also result in Familial Chylomicronemia Syndrome.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Familial Chylomicronemia Syndrome Epidemiology Segmentation in the 7MM<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Total Familial Chylomicronemia Syndrome Diagnosed Prevalent Cases<\/li>\n<li>Familial Chylomicronemia Syndrome Age-specific Diagnosed Prevalent Cases<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Download the report to understand which factors are driving Familial Chylomicronemia Syndrome Epidemiology Trends @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/familial-chylomicronemia-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Familial Chylomicronemia Syndrome Epidemiological Insights<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Familial Chylomicronemia Syndrome Market Insights<\/strong><\/p>\n<p style=\"text-align: justify;\">There are several compounds in the development pipeline primarily focusing on improving the LPL-mediated clearance of TGRL by reducing the activity of proteins such as apolipoprotein C-III and ANGPTL 3\/4 that block LPL. Although, despite the emerging drugs, there is still a major requirement to recognize the unmet need for effective Familial Chylomicronemia Syndrome treatment options that reduce symptoms and cure the disease.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Familial Chylomicronemia Syndrome Market Size<\/strong><\/p>\n<p style=\"text-align: justify;\">According to DelveInsight analysis, the United States accounted for total market size of USD 2 million of FCS in year 2022 in the 7MM. The market size of the 7MM is anticipated to increase during the forecast period due to the expected launch of emerging therapies.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>To know more about Familial Chylomicronemia Syndrome Treatment options, visit @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/familial-chylomicronemia-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Familial Chylomicronemia Syndrome Drugs<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Familial Chylomicronemia Syndrome Companies and Therapies<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Ionis Pharmaceuticals Inc.: Olezarsen<\/li>\n<li>Akcea Therapeutics: AKCEA-ANGPTL3-LRx<\/li>\n<li>Novartis Pharmaceuticals: LCQ908<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Familial Chylomicronemia Syndrome Drugs Uptake<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>Olezarsen<\/strong>, formerly known as IONIS-APOCIII-LRx and AKCEA-APOCIII-LRx, is a ligand-conjugated (LICA) investigational antisense medicine designed to inhibit the production of Apoc-III in the liver. It is being investigated in Phase III for FCS patients. The drug has also been granted with FTD by the US FDA.<\/p>\n<p style=\"text-align: justify;\"><strong>ARO-APOC3<\/strong> is designed to reduce the production of Apolipoprotein C-III (Apoc-III), a component of triglyceride-rich lipoproteins (TRLs) including VLDL and chylomicrons, and is a key regulator of triglyceride metabolism. Arrowhead clinical trials for ARO-APOC3 have advanced into Phase III. The US FDA has grant orphan drug designation to ARO-APOC3 for FCS treatment.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Learn more about the Familial Chylomicronemia Syndrome Pipeline Therapies in clinical trials @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/familial-chylomicronemia-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Familial Chylomicronemia Syndrome Market Landscape<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Familial Chylomicronemia Syndrome Market Report<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Coverage- 7MM<\/li>\n<li>Familial Chylomicronemia Syndrome Companies- <strong><em>Ionis Pharmaceuticals Inc., Akcea Therapeutics, Novartis Pharmaceuticals, Arrowhead Pharmaceuticals, UniQure Biopharma B.V.,<\/em><\/strong> and others.<\/li>\n<li>Familial Chylomicronemia Syndrome Pipeline Therapies in the various stages of development include <strong><em>ARO-APOC3, sterile normal saline (0.9% NaCl), LCQ908, Olezarsen, Volanesorsen, AKCEA-ANGPTL3-LRx<\/em><\/strong>, and others.<\/li>\n<li>Familial Chylomicronemia Syndrome Market Dynamics: Familial Chylomicronemia Syndrome Market Drivers and Barriers<\/li>\n<li>Familial Chylomicronemia Syndrome Market Access and Reimbursement, Unmet Needs, and Future Perspectives<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Discover more about Familial Chylomicronemia Syndrome Drugs in development @ <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/familial-chylomicronemia-syndrome-market?utm_source=abnewswire&amp;utm_medium=pressrelease&amp;utm_campaign=ypr\" target=\"_blank\">Familial Chylomicronemia Syndrome Ongoing Clinical Trials Analysis<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Content<\/strong><\/p>\n<p style=\"text-align: justify;\">1. Key Insights<\/p>\n<p style=\"text-align: justify;\">2. Familial Chylomicronemia Syndrome&nbsp;Market Report Introduction<\/p>\n<p style=\"text-align: justify;\">3. Familial Chylomicronemia Syndrome Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">4.&nbsp;Familial Chylomicronemia Syndrome&nbsp;Epidemiology and Market Methodology<\/p>\n<p style=\"text-align: justify;\">5. Executive Summary of Familial Chylomicronemia Syndrome<\/p>\n<p style=\"text-align: justify;\">6. Key Events<\/p>\n<p style=\"text-align: justify;\">7. Disease Background and Overview Familial Chylomicronemia Syndrome<\/p>\n<p style=\"text-align: justify;\">8.&nbsp;Familial Chylomicronemia Syndrome&nbsp;Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">9.&nbsp;Familial Chylomicronemia Syndrome&nbsp;Patient Journey<\/p>\n<p style=\"text-align: justify;\">10.&nbsp;Familial Chylomicronemia Syndrome&nbsp;Marketed Drugs<\/p>\n<p style=\"text-align: justify;\">11.&nbsp;Familial Chylomicronemia Syndrome&nbsp;Emerging Drugs<\/p>\n<p style=\"text-align: justify;\">12. Familial Chylomicronemia Syndrome: The 7MM Analysis<\/p>\n<p style=\"text-align: justify;\">13.&nbsp;Familial Chylomicronemia Syndrome&nbsp;SWOT<\/p>\n<p style=\"text-align: justify;\">14.&nbsp;Familial Chylomicronemia Syndrome&nbsp;Unmet Needs<\/p>\n<p style=\"text-align: justify;\">15. Key Opinion Leaders&rsquo; Views<\/p>\n<p style=\"text-align: justify;\">16.&nbsp;Familial Chylomicronemia Syndrome&nbsp;Market Access and Reimbursement<\/p>\n<p style=\"text-align: justify;\">17. Appendix<\/p>\n<p style=\"text-align: justify;\">18. DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">19. Disclaimer<\/p>\n<p style=\"text-align: justify;\">20. About DelveInsight<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>About Us<\/strong><\/p>\n<p style=\"text-align: justify;\">DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&amp;D, Strategy Formulation, Operations, Competitive Intelligence, Healthcare Market Research Reports, Competitive Landscaping, and Mergers and acquisitions.&nbsp;<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_56402.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Yash Bhardwaj<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=familial-chylomicronemia-syndrome-was-around-usd-15-million-in-2022-estimates-delveinsight\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304  S. Jones Blvd #2432<br \/><strong>City:<\/strong> Las Vegas<br \/><strong>State:<\/strong> NV<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/stem-cell-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/stem-cell-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/stem-cell-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=familial-chylomicronemia-syndrome-was-around-usd-15-million-in-2022-estimates-delveinsight\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&ldquo;The Familial Chylomicronemia Syndrome Market is expected to surge due to the disease&rsquo;s increasing prevalence and awareness during the forecast period (2023-2034). Furthermore, launching various multiple- Familial Chylomicronemia Syndrome pipeline products will significantly revolutionize the Familial Chylomicronemia Syndrome market dynamics&rdquo; &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/familial-chylomicronemia-syndrome-was-around-usd-15-million-in-2022-estimates-delveinsight_685474.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[405,406,413],"tags":[],"class_list":["post-685474","post","type-post","status-publish","format-standard","hentry","category-Health-Medicine","category-Pharmaceuticals-Biotech","category-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/685474","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=685474"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/685474\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=685474"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=685474"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=685474"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}